Boston Scientific (BSX) Earns “Buy” Rating from BMO Capital Markets

BMO Capital Markets restated their buy rating on shares of Boston Scientific (NYSE:BSX) in a report issued on Wednesday. BMO Capital Markets currently has a $31.00 price target on the medical equipment provider’s stock.

BSX has been the topic of several other reports. UBS reaffirmed a buy rating and set a $31.00 price target (up from $30.00) on shares of Boston Scientific in a research note on Tuesday, August 1st. SunTrust Banks set a $34.00 target price on shares of Boston Scientific and gave the stock a buy rating in a research report on Tuesday, October 31st. Zacks Investment Research cut shares of Boston Scientific from a buy rating to a hold rating in a research report on Monday, October 30th. BidaskClub cut shares of Boston Scientific from a hold rating to a sell rating in a research report on Saturday, August 26th. Finally, Oppenheimer reissued a hold rating on shares of Boston Scientific in a research report on Wednesday, August 9th. One analyst has rated the stock with a sell rating, four have assigned a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of Buy and a consensus price target of $30.61.

Shares of Boston Scientific (NYSE:BSX) opened at $26.15 on Wednesday. Boston Scientific has a 12 month low of $20.03 and a 12 month high of $29.93. The stock has a market cap of $35,909.07, a PE ratio of 21.43, a price-to-earnings-growth ratio of 2.02 and a beta of 0.96. The company has a current ratio of 0.72, a quick ratio of 0.50 and a debt-to-equity ratio of 0.58.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.31. Boston Scientific had a net margin of 9.55% and a return on equity of 23.60%. The company had revenue of $2.22 billion for the quarter, compared to analysts’ expectations of $2.21 billion. During the same period last year, the company earned $0.27 EPS. The firm’s revenue for the quarter was up 5.6% compared to the same quarter last year. sell-side analysts predict that Boston Scientific will post 1.25 earnings per share for the current fiscal year.

In other Boston Scientific news, insider Valley Gold Master Fund L. Sun purchased 408,006 shares of the business’s stock in a transaction that occurred on Tuesday, November 28th. The shares were purchased at an average price of $0.45 per share, for a total transaction of $183,602.70. Also, EVP Michael P. Phalen sold 15,500 shares of the firm’s stock in a transaction that occurred on Wednesday, November 29th. The shares were sold at an average price of $26.66, for a total transaction of $413,230.00. The disclosure for this sale can be found here. Insiders sold 414,698 shares of company stock worth $12,013,153 in the last 90 days. 0.74% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of BSX. Russell Investments Group Ltd. raised its holdings in Boston Scientific by 23.6% in the second quarter. Russell Investments Group Ltd. now owns 989,984 shares of the medical equipment provider’s stock valued at $27,436,000 after buying an additional 189,132 shares during the period. NGAM Advisors L.P. raised its holdings in Boston Scientific by 12.4% in the second quarter. NGAM Advisors L.P. now owns 49,840 shares of the medical equipment provider’s stock valued at $1,382,000 after buying an additional 5,513 shares during the period. Janney Montgomery Scott LLC raised its holdings in Boston Scientific by 1.8% in the second quarter. Janney Montgomery Scott LLC now owns 53,602 shares of the medical equipment provider’s stock valued at $1,486,000 after buying an additional 929 shares during the period. CIBC Asset Management Inc raised its holdings in Boston Scientific by 0.5% in the second quarter. CIBC Asset Management Inc now owns 129,853 shares of the medical equipment provider’s stock valued at $3,600,000 after buying an additional 689 shares during the period. Finally, Lockheed Martin Investment Management Co. purchased a new position in Boston Scientific in the second quarter valued at approximately $3,798,000. Hedge funds and other institutional investors own 90.55% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Boston Scientific (BSX) Earns “Buy” Rating from BMO Capital Markets” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/12/03/boston-scientific-bsx-earns-buy-rating-from-bmo-capital-markets.html.

About Boston Scientific

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Analyst Recommendations for Boston Scientific (NYSE:BSX)

What are top analysts saying about Boston Scientific Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Boston Scientific Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit